SAB Biotherapeutics(SABS)
$2.96-0.12 (-3.90%)
SABS
SAB Biotherapeutics hedge funds
$2.96
At close:-0.12 (-3.90%)
Want to see SABS full AI Analyst Report?
SAB Biotherapeutics (SABS) Hedge Fund Trading Activity
330 Followers
Trend: ▲ Hedge Funds Increased Holdings by 428.8K Shares Last Quarter
Hedge Fund Holdings in SABS
Based on the 13F filings of 489 Hedge Funds tracked by TipRanks, as submitted to the SEC.
Hedge Fund Confidence Signal
Hedge Fund Activity
Activity
Star Ranking
| Added | 917.51% | $11,957,462 | <0.01% | ||||
| Perceptive Advisors LLC | Added | 3.04% | $25,847,254 | 0.39% | |||
| RA Capital Management | Not Changed | 0.00% | $17,165,850 | 0.15% | |||
| Woodline Partners LP | Reduced | -58.61% | $4,603,385 | 0.01% | |||
| Blackstone Inc. | Sold Out | -100.00% | $0 | 0.00% |
FAQ
Which hedge funds hold SAB Biotherapeutics?
The hedge funds that hold the most shares in SAB Biotherapeutics are BlackRock, Inc., Stephen A. Schwarzman and Joseph Edelman.
Are hedge funds buying or selling SABS?
In the last quarter hedge funds have Increased their holdings in SAB Biotherapeutics by 428.8K shares.
Where can I see a list of the best rated hedge funds?
You can see a list of the best hedge funds here.
Who is the best-performing hedge fund manager?
The top-rated hedge fund managers can be seen here: Top Hedge Fund Managers
Does Warren Buffet hold shares in SAB Biotherapeutics stock?
Warren Buffet currently does not own shares in SAB Biotherapeutics.
What is a 13F filing, and how does it help investors?
A 13F form, also known as a "Report of Investment Manager," is a quarterly report that investment advisors registered with the Securities and Exchange Commission (SEC) must file if they manage at least $100 million in assets. The 13F form lists all of the publicly traded securities that the investment advisor owns as of the end of the reporting period. To read more about the 13F, click here

